You are here

  • Home
  • Archive
  • Volume 84, Issue 8
  • Monitoring intravenous immunoglobulin dosing regimens in chronic inflammatory demyelinating polyneuropathy: search for a biomarker

Article Text

Article menu
Download PDFPDF
Editorial commentary
Monitoring intravenous immunoglobulin dosing regimens in chronic inflammatory demyelinating polyneuropathy: search for a biomarker
  1. Benjamin R Wakerley,
  2. Nobuhiro Yuki
  1. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
  1. Correspondence to Professor Nobuhiro Yuki, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Unit 09-01, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore; mdcyuki{at}nus.edu.sg

https://doi.org/10.1136/jnnp-2012-304826

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The clinical effectiveness and relative ease of administering intravenous immunoglobulin (IVIG) make it the preferred treatment option for several immune mediated conditions including chronic inflammatory demyelinating polyneuropathy (CIDP). Timing and dosage of IVIG vary considerably in CIDP between patients. The cost implications for establishing sensitive and reliable biomarkers, which accurately predict IVIG dosing regimens and avoid overtreatment are therefore considerable and warrant investigation. In this issue, Kuitwaard and colleagues examine the variability of serum IgG levels in patients receiving IVIG for treatment of CIDP.1 They demonstrate …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and review Not commissioned; externally peer reviewed.

    Linked Articles